FY2027 EPS Estimates for Precigen Decreased by HC Wainwright

Precigen, Inc. (NASDAQ:PGEN) – Investment analysts at HC Wainwright lowered their FY2027 earnings per share (EPS) estimates for Precigen in a note issued to investors on Thursday, March 20th. HC Wainwright analyst S. Ramakanth now expects that the biotechnology company will post earnings of $0.18 per share for the year, down from their previous estimate of $0.20. HC Wainwright has a “Buy” rating and a $6.00 price objective on the stock. The consensus estimate for Precigen’s current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for Precigen’s FY2028 earnings at $0.40 EPS and FY2029 earnings at $0.66 EPS.

Precigen (NASDAQ:PGEN) last announced its quarterly earnings data on Wednesday, March 19th. The biotechnology company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.02. The company had revenue of $1.19 million for the quarter, compared to the consensus estimate of $1.30 million. Precigen had a negative net margin of 3,521.68% and a negative return on equity of 123.06%.

Separately, JMP Securities reiterated a “market outperform” rating and set a $5.00 target price on shares of Precigen in a research note on Tuesday, January 14th. Two research analysts have rated the stock with a sell rating and four have given a buy rating to the stock. Based on data from MarketBeat, Precigen currently has an average rating of “Hold” and an average price target of $7.00.

Precigen Stock Up 0.6 %

NASDAQ:PGEN opened at $1.81 on Friday. Precigen has a 52 week low of $0.65 and a 52 week high of $2.17. The stock has a market cap of $530.09 million, a price-to-earnings ratio of -3.29 and a beta of 1.58. The company’s 50 day moving average price is $1.61 and its 200-day moving average price is $1.15.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in PGEN. BNP Paribas Financial Markets purchased a new stake in Precigen during the 4th quarter valued at $27,000. Envestnet Asset Management Inc. increased its position in Precigen by 29.0% during the fourth quarter. Envestnet Asset Management Inc. now owns 26,343 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 5,915 shares during the last quarter. Boothbay Fund Management LLC purchased a new stake in Precigen during the fourth quarter valued at $35,000. Stifel Financial Corp lifted its holdings in Precigen by 94.9% in the third quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 15,680 shares during the period. Finally, RPO LLC purchased a new position in Precigen in the fourth quarter worth about $47,000. 33.51% of the stock is owned by hedge funds and other institutional investors.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.